Orexo AB - Product Pipeline Review - Q4 2010

Global Markets Direct, December 2010, Pages: 65

Orexo AB – Product Pipeline Review – Q4 2010

Summary

Global Market Direct’s pharmaceuticals report, “Orexo AB - Product Pipeline Review - Q4 2010” provides data on the company’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company’s corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Orexo AB - Brief company overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Orexo AB human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Orexo AB with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Orexo AB’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Orexo AB’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Orexo AB in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Orexo AB’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Orexo AB.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Orexo AB and identify potential opportunities in those areas.

List of Tables
List of Figures
Orexo AB Snapshot
Orexo AB Overview
Key Information
Key Facts
Orexo AB – Research and Development Overview
Key Therapeutic Areas
Orexo AB – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Orexo AB – Pipeline Products Glance
Orexo AB Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Orexo AB–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Orexo AB – Drug Profiles
OX914
Product Description
Mechanism of Action
R&D Progress
OX19
Product Description
Mechanism of Action
R&D Progress
OX219
Product Description
Mechanism of Action
R&D Progress
OX-CLI
Product Description
Mechanism of Action
R&D Progress
OX-MPI
Product Description
Mechanism of Action
R&D Progress
OX2477
Product Description
Mechanism of Action
R&D Progress
OX30
Product Description
Mechanism of Action
R&D Progress
OX641
Product Description
Mechanism of Action
R&D Progress
Orexo AB – Pipeline Analysis
Orexo AB – Pipeline Products by Therapeutic Class
Orexo AB Pipeline Products By Target
Orexo AB – Pipeline Products by Route of Administration
Orexo AB – Pipeline Products by Molecule Type
Orexo AB – Recent Pipeline Updates
Orexo AB – Company Statement
Orexo AB – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Feb 04, 2010: ProStrakan Announces Canadian Regulatory Filing Of Abstral
Sep 06, 2009: ProStrakan Announces FDA Acceptance Of Abstral Filing in the US
Jul 24, 2009: Orexo Announces Positive Phase III Results For KW-2246 In Japan
Jun 30, 2009: Orexo Announces That Abstral Is Ready For Launch In France
Mar 24, 2009: Orexo Announces Clinical Results From An Experimental Phase IIa Study Of OX914
Mar 02, 2009: Orexo’s Abstral Receives Two Further Large EU Market Approvals In France Aand Spain
Dec 11, 2008: Abstral Receives Marketing Approval In Germany
Oct 31, 2008: Orexo AB Announces That UK Medicines And Healthcare Products Regulatory Agency (MHRA) Issued UK Marketing Approval For Abstral
Sep 02, 2008: Orexo Initiates Clinical Phase II Program For OX914 - A New Product Candidate For The Treatment Of Inflammatory Airway Diseases
Sep 02, 2008: Orexo Initiates Clinical Phase II Program For OX914 - A New Product Candidate For The Treatment Of Inflammatory Airway Diseases
Financial Deals Landscape
Orexo AB, Deals Volume Summary, 2004 to YTD 2010
Orexo AB, Deals Summary By Region, 2004 to YTD 2010
Orexo AB, Deals Summary, 2004 to YTD 2010
Orexo AB Detailed Deal Summary
Asset Purchase
Meda Acquires Commercializtion Rights Of Sublinox And OX-NLA From Orexo
Acquisition
Orexo Acquires PharmaKodex
Orexo Acquires Biolipox
Kibion Acquires Noster System
Venture Financing
PharmaKodex Secures $13.43 Million In Series A Financing
Orexo Enters Into A Co-Development Agreement With Healthcare Company
Orexo Enters Into Co-Marketing Agreement With Hospira
ProStrakan Forms Joint Venture With Orexo
Gedeon Richter Enters Into A Distribution Agreement With Orexo
Licensing Agreements
Orexo Enters Into Licensing Agreement With Novartis Pharmaceuticals
Orexo Enters Into Licensing Agreement With NovaMed
Orexo Extends Licensing Agreement With Boehringer
Orexo Extends Its Licensing Agreement With ProStrakan
ProStrakan Forms In-Licensing Agreement With Orexo
Orexo Enters Into Licensing Agreement With Boehringer Ingelheim
Endo Pharmaceuticals Enters Into Licensing Agreement With Orexo
Orexo Terminates Its Licensing Agreement With Endo Pharmaceuticals
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Customers who bought this item also bought

• eLEARNING - Global Strategic Business Report
• Aerospace and Defense Industry - Global Strategic Business Report
• Commercial And Military Flight Simulation - Global Strategic Business Report
• Sports and Fitness Nutrition - Global Strategic Business Report
• Education Services - Global Strategic Business Report
• Charter Schools - Global Outlook
• Defense Robotics - Global Strategic Business Report
• Distance Learning - Global Outlook
• The Global UAV Payload Market 2012-2022
• The UK Education Industry Forecast to 2015 - Dominance of Higher Education Sector